<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04289207</url>
  </required_header>
  <id_info>
    <org_study_id>0620200130</org_study_id>
    <nct_id>NCT04289207</nct_id>
  </id_info>
  <brief_title>Phase II Trial of Romiplostim With Danazol in Patients With Eltrombopag-resistant Immune Thrombocytopenia</brief_title>
  <official_title>Phase II Trial of Romiplostim With Danazol in Patients With Eltrombopag-resistant Immune Thrombocytopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kyowa Kirin Korea Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, we tried to demonstrate clinical benefit of additive danazol to romiplostim
      therapy in patients with eltrombopag-resistant immune thrombocytopenia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients with eltrombopag-resistant immune thrombocytopenia are treated with romiplostim
      and danazol. The efficacy and toxicity of treatment will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>week 8</time_frame>
    <description>proportion of patients with platelet count over 50x10^9/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to best response</measure>
    <time_frame>week 24</time_frame>
    <description>time interval between initiation of treatment and best response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response duration</measure>
    <time_frame>week 24</time_frame>
    <description>period of time with platelet count over 50x10^9/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on quality of life</measure>
    <time_frame>week 24</time_frame>
    <description>changes in EORTC QLQ-C30 scores</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Immune Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>Romiplostim and danazol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment group (romiplostim and danazol)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Romiplostim and danazol</intervention_name>
    <description>Treatment with romiplostim and danazol</description>
    <arm_group_label>Romiplostim and danazol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged over 18 years

          -  diagnosed with immune thrombocytopenia (bone marrow examination is not necessary)

          -  failed to achieve platelet count over 50X10^9/L with eltrombopag

          -  ECOG performance status 0,1,2

          -  available to obtain informed consent

        Exclusion Criteria:

          -  Hepatitis B or C carriers

          -  HIV positive patients

          -  diagnosed with systemic lupus erythematosus or other autoimmune disorders

          -  unable to intake orally or absorb through gastrointestinal tract

          -  pregnant or breast-feeding

          -  diagnosed with uncontrolled seizure or other neuropsychiatric disorders

          -  diagnosed with clinically significant cardiovascular events within 6 months or dyspnea
             on exertion evaluated to New York Heart Association Functional Classification III or
             IV

          -  diagnosed with clinically significant cerebrovascular disorders

          -  previously diagnosed or treated with thromboembolism

          -  current treating malignant diseases

          -  currently accompanied by uncontrolled infection or active bleeding

          -  with blood test results as follows; total bilirubin &gt; 2xUNL(upper normal limit),
             AST/ALT &gt; 1.5xUNL, creatinine &gt; 1.5xUNL, glomerular filtration rate &lt; 30ml/min/1.73m^2

          -  registered to other clinical trials for treatment of immune thrombocytopenia

          -  judged to be inappropriate for clinical trial by doctor in charge
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Youngil Koh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Youngil Koh</last_name>
    <phone>82-02-2072-7217</phone>
    <email>go01@snu.ac.kr</email>
  </overall_contact>
  <reference>
    <citation>Cooper N, Bussel J. The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol. 2006 May;133(4):364-74. Review.</citation>
    <PMID>16643442</PMID>
  </reference>
  <reference>
    <citation>Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood. 2009 Mar 5;113(10):2161-71. doi: 10.1182/blood-2008-04-150078. Epub 2008 Nov 3. Erratum in: Blood. 2009 May 7;113(19):4822.</citation>
    <PMID>18981291</PMID>
  </reference>
  <reference>
    <citation>Wong RSM, Saleh MN, Khelif A, Salama A, Portella MSO, Burgess P, Bussel JB. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017 Dec 7;130(23):2527-2536. doi: 10.1182/blood-2017-04-748707. Epub 2017 Oct 17. Erratum in: Blood. 2018 Feb 8;131(6):709.</citation>
    <PMID>29042367</PMID>
  </reference>
  <reference>
    <citation>Khellaf M, Viallard JF, Hamidou M, Cheze S, Roudot-Thoraval F, Lefrere F, Fain O, Audia S, Abgrall JF, Michot JM, Dauriac C, Lefort S, Gyan E, Niault M, Durand JM, Languille L, Boutboul D, Bierling P, Michel M, Godeau B. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica. 2013 Jun;98(6):881-7. doi: 10.3324/haematol.2012.074633. Epub 2013 Feb 26.</citation>
    <PMID>23445876</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 25, 2020</study_first_submitted>
  <study_first_submitted_qc>February 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2020</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Youngil Koh</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Danazol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

